NCT07144813 Post-Approval Study of the Neuspera Sacral Neuromodulation System
| NCT ID | NCT07144813 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Neuspera Medical, Inc. |
| Condition | Urinary Urgency Incontinence |
| Study Type | INTERVENTIONAL |
| Enrollment | 116 participants |
| Start Date | 2025-09-03 |
| Primary Completion | 2029-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 116 participants in total. It began in 2025-09-03 with a primary completion date of 2029-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective, multi-center, single-arm, post-approval study is designed to assess the long-term safety and efficacy data of the Neuspera Sacral Neuromodulation (SNM) System following commercial approval of the Neuspera SNM System. Participants in this study received intervention/implanted in Phase I or Phase II of the Neuspera SANS\_UUI (NSM-004) Study.
Eligibility Criteria
Inclusion Criteria: * Subjects in the SANS-UUI Phase I or Phase II study Exclusion Criteria: * None
Contact & Investigator
Osvaldo Padron, MD
PRINCIPAL INVESTIGATOR
Florida Urology Partners
Frequently Asked Questions
Who can join the NCT07144813 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, studying Urinary Urgency Incontinence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07144813 currently recruiting?
Yes, NCT07144813 is actively recruiting participants. Contact the research team at mark.vollmer@neuspera.com for enrollment information.
Where is the NCT07144813 trial being conducted?
This trial is being conducted at San Diego, United States, San Diego, United States, Tampa, United States, Fort Wayne, United States and 11 additional locations.
Who is sponsoring the NCT07144813 clinical trial?
NCT07144813 is sponsored by Neuspera Medical, Inc.. The principal investigator is Osvaldo Padron, MD at Florida Urology Partners. The trial plans to enroll 116 participants.